Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
R&D Innovation & Pharma Drug-Device Pricing
Posted on September 26th, 2016 by Dr. Makarand Jawadekar, Ph.D
Pharma R&D
The media as of late has given a lot of coverage to the “price gouging” that pharmaceutical company Mylan engaged in with its injection device EpiPen. Continue reading “R&D Innovation & Pharma Drug-Device Pricing” »
Is a new Alzheimer’s disease drug in the offing?
Posted on September 23rd, 2016 by Patrick C. May, PH.D.
Pharma R&D
A high profile paper describing a prospective new therapy for Alzheimer’s disease (AD) was being shared around the internet recently. The paper, “The antibody aducanumab reduces Ab plaques in Alzheimer’s disease,” authored by Sevigny et al., was published on-line in Nature (Sevigny et al., 2016) and describes the preclinical and early clinical development of aducanumab, Continue reading “Is a new Alzheimer’s disease drug in the offing?” »
Top 10 Most Talked-About Articles on Zika
Posted on September 21st, 2016 by Betsy Davis
Pharma R&D
The Zika virus (ZIKV) has been linked to severe birth defects, causing fear of the virus around the globe. As people, particularly pregnant women, take measures to protect themselves from exposure to mosquitos that might be carrying Zika, scientists are working hard to better understand the nature of the virus Continue reading “Top 10 Most Talked-About Articles on Zika” »
Easing the Pain in Monitoring Literature for Adverse Drug Events
Posted on September 20th, 2016 by Neal Katz
Pharmacovigilance
Over the past year, we have heard about the various challenges associated with the cumbersome task of monitoring scientific literature for adverse drug events (AE) from thought leaders on this blog. Pharmacovigilance professionals have written about the literature monitoring and review process, the recent EMA Medical Literature Monitoring initiative, and the importance of literature search strategies. Continue reading “Easing the Pain in Monitoring Literature for Adverse Drug Events” »
Finding Adverse Event Data on Social Media
Posted on September 19th, 2016 by Sherry Winter
Pharmacovigilance
Have you ever complained about an unpleasant health issue (maybe a strange ache or sudden difficulty sleeping) on your Facebook page? Ever tweeted a picture of a swollen or discolored part of your body? Continue reading “Finding Adverse Event Data on Social Media” »
Women and minorities in clinical trials
Posted on September 16th, 2016 by Jeffrey Paul, PhD
Pharma R&D
You are a female and/or a minority and concerned if you will respond to your medication. So you read the product label, asking yourself, “Do I see myself described as a patient in the drug testing trials?” Continue reading “Women and minorities in clinical trials” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.
